INSTRUCTIONS FOR AUTHORS

ANZ NUCLEAR MEDICINE welcomes submission (via email or CD-ROM) of material related to the scientific, technological and clinical aspects of nuclear medicine. Original research, case reports, reviews and letters to the Editor are encouraged.

Send material for publication to Judi Anderson, ANZSNM Secretariat, via email anzsnm@21century.com.au. The ANZSNM Secretariat postal address is, ANZSNM Secretariat, PO Box 7105, Upper Ferntree Gully, VIC 3156. Tel: (03) 9756 0128, Fax: (03) 9753 6372.

I. ORIGINAL MANUSCRIPTS

Papers submitted for publication must be in electronic format. Files should be submitted in a standard word processing format; Microsoft Word is preferred. Do not use automatic numbering or footnotes for references. If submitting by CD-ROM it must (a) be clearly labelled with the name of the author, item title, word processing program and version, and file name used and (b) contain only the latest manuscript and illustration files related to the submission. It is expected that authors have performed a literature search by using sources such as Medline or, Pubmed.

Title Page: Include title, authors and their affiliations, institution where work was performed, abbreviated title, and name, address, telephone and fax numbers, name and address and e mail address of the corresponding author.

Abstract: There should be a structured abstract of no more than 250 words. The abstract should include the Purpose of the Report; Materials and Methods; Results; and Conclusions, divided into four separate paragraphs. Abbreviations of isotopes and radiopharmaceuticals should be used. Three to six Key Words for indexing purposes should appear after the abstract.

Text: References should be cited with parentheses in numerical order as they appear. Only those references that are considered essential should be included. A summary may be included at the discretion of the author. Footnotes should be limited and should be typed at the bottom of the appropriate page. Isotopes: When abbreviating isotopes, designate them in the following manner instead of using superscripts: I-125,
In-113m, Tc-99m. Radiopharmaceuticals: Radiopharmaceuticals should be listed with the isotope first followed by the chemical form. Abbreviations of isotopes are preferred but not required (Tc-99m sodium pertechnetate or technetium-99m sodium pertechnetate; I-131 human serum albumin or iodine-131 human serum albumin). Abbreviating radiopharmaceuticals: In using abbreviations to shorten the lengthy name of a radiopharmaceutical, the full name should be spelled out completely the first time it is mentioned, followed by the abbreviation in parentheses (Tc-99m diethylenetriaminepentaacetic acid (DTPA); thereafter Tc-99m DTPA). Thereafter abbreviations may be used. In the abstract, abbreviations may be used throughout without explanation.

Radiopharmaceutical doses and units: Only SI units are acceptable. If it important in the context to use non-SI units (eg curie), this should be in parentheses after the SI unit.

Illustrations: Separate legends should be prepared for each figure/illustration. Photographs should not contain distracting smudges, markings, writing, or hand lettering. Hand lettering is usually not of sufficient quality for publication. Electronic art should be submitted as either a TIFF (tagged image file format) or an EPS (encapsulated postscript) file. Line art must have a resolution of at least 300dpi (dots per inch), and electronic photographs - radiographs, CT scans, and MRI studies - and scanned images must have a resolution of at least 300 dpi. If fonts are used in the artwork, they must be converted to paths or outlines or they must be embedded in the files. Colour images must be saved and submitted as CMYK files. Files can be submitted on a CD-ROM. Please note that artwork generated from office suite programs such as Power Point, Corel Draw, and MS Word and artwork in compressed format (JPEG or GIF files) cannot be used.

References: These should be double spaced in numerical order (not alphabetically by author), and should conform to the following style:
1. Sojan SM, Smyth DR, Tsopelas C et al, Pharmacokinetics and normal scintigraphic appearance of 99mTc aprotinin. Nucl Med Commun, 2005; 26: 535-9.
2. Chatterton BE: Gastric Motility: In Ell PJ & Gambhir SS ed: Nuclear Medicine in Clinical Diagnosis and Treatment, (3rd edition, Vol 1), Churchill Livingstone, 2004, 805-35

Copyright Transfer Agreement:

Each author must read and sign the following statements which should be submitted with the work.
Except for copyright, other proprietary rights related to the Work shall be retained by the authors. To reproduce any text, figures, tables, or illustrations from this Work in future works of their own, the authors must obtain written permission from ANZ Nuclear Medicine, such permission cannot be unreasonably withheld.
Each author warrants that the Work is original and that he or she has full power to enter into this agreement. Neither this or similar Work has been published or submitted for publication elsewhere while under consideration by ANZ Nuclear Medicine. Each author certifies that he or she has participated sufficiently in the intellectual content, the analysis of data, if applicable, and the writing of the Work, has reviewed the final version, and approves it for publication. Moreover, should the editors of the Publication request the data upon which the work is based, it will be produced.
If excerpts (text, figures, tables, or illustrations) from copyrighted works are included, a written release will be secured by the authors prior to submission, and credit will be acknowledged. Each author further warrants that written releases from patients whose names or photographs are submitted have been obtained.
Each author certifies that he or she has no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article, except as disclosed on a separate attachment
Each author certifies that his or her institution has approved through a properly constituted ethics committee/ IRB the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and humane principles of research.

TRANSFER OF COPYRIGHT

AUTHORS' OWN WORK: In consideration of ANZ Nuclear Medicine's publication of the Work, the authors hereby transfer to ANZ Nuclear Medicine all copyright ownership worldwide, in all languages, and in all forms of media. Should the Work not be published, ANZ Nuclear shall give prompt notice of its decision to the corresponding author, this agreement shall terminate, and the author shall be under no further liability or obligation.

Signature_____ Printed name_____ Date_____

V. Manuscript Checklist

- CD-ROM Disk with paper and high resolution images saved,
- Copyright transfer form signed by all authors.
- Cover letter
- Permission to reproduce copyrighted materials or signed patient consent forms
- Acknowledgments listed for grants and technical support